Sangamo Therapeutics, Inc., a genomic medicine company, announced the pricing of a $23.0 million underwritten offering. The offering comprises 12,235,000 shares of common stock and pre-funded warrants to purchase 34,398,393 shares, along with accompanying warrants to purchase 46,633,393 shares of common stock. Each share of common stock and accompanying warrant is priced at $0.50, while each pre-funded warrant and accompanying warrant is priced at $0.49. Warrants have an exercise price of $0.75 per share, becoming exercisable six months post-issuance with a six-year expiry. The offering is expected to conclude around May 14, 2025, with the proceeds aimed at working capital and general corporate purposes. Cantor is acting as the sole book-running manager for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.